A multicenter retrospective analysis from Brazil reported real-world outcomes for Lu-177 PSMA-I&T in heavily pretreated metastatic castration-resistant prostate cancer. The study found a 44.2% biochemical response rate, supporting ongoing clinical use of PSMA-targeted radionuclide therapy in later-line settings. The findings add to the growing body of observational evidence for radioligand performance outside tightly controlled trial environments. For clinicians and biotech partners tracking next-generation theranostics, the result underscores continued demand for PSMA radiopharmaceuticals and the need for real-world benchmarks alongside trial endpoints.